13 hours ago
1
- Atai Life Sciences (NASDAQ:ATAI) is off ~12% in after-hours trading Friday after a company it has a significant investment in reported that a phase 2b study of a schizophrenia asset missed its primary endpoint.
- Recognify Life Sciences said that inidascamine
English (US) ·